CD19 and B-cell non-Hodgkin lymphoma: Autologous anti CD19 CAR T cell KTE-X19 therapy used for patients with r/r mantle cell lymphoma which is a B cell non-Hodgkin’s lymphoma with aggressive clinical course but the therapy induced durable remission by initially eliminating circulating CD19 expressing malignant cells thus narrows the exhaustion of anti CD19 CAR T cells [58].